0000899243-21-042710.txt : 20211103
0000899243-21-042710.hdr.sgml : 20211103
20211103162018
ACCESSION NUMBER: 0000899243-21-042710
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211026
FILED AS OF DATE: 20211103
DATE AS OF CHANGE: 20211103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SV7 Impact Medicine Fund LP
CENTRAL INDEX KEY: 0001780602
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40925
FILM NUMBER: 211375690
BUSINESS ADDRESS:
STREET 1: 71 KINGSWAY
CITY: LONDON
STATE: X0
ZIP: WC2B 6ST
BUSINESS PHONE: 44 20 7421 7081
MAIL ADDRESS:
STREET 1: 71 KINGSWAY
CITY: LONDON
STATE: X0
ZIP: WC2B 6ST
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SV7 (IMF) GP LLP
CENTRAL INDEX KEY: 0001889859
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40925
FILM NUMBER: 211375689
BUSINESS ADDRESS:
STREET 1: 71 KINGSWAY
CITY: LONDON
STATE: X0
ZIP: WC2B 6ST
BUSINESS PHONE: 44 20 7421 7081
MAIL ADDRESS:
STREET 1: 71 KINGSWAY
CITY: LONDON
STATE: X0
ZIP: WC2B 6ST
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xilio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840233
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851623397
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-833-1027
MAIL ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2021-10-26
2021-10-28
1
0001840233
Xilio Therapeutics, Inc.
XLO
0001780602
SV7 Impact Medicine Fund LP
71 KINGSWAY
LONDON
X0
WC2B 6ST
UNITED KINGDOM
0
0
1
0
0001889859
SV7 (IMF) GP LLP
71 KINGSWAY
LONDON
X0
WC2B 6ST
UNITED KINGDOM
0
0
1
0
Common Stock
2021-10-26
4
C
0
998544
A
998544
D
Common Stock
2021-10-26
4
C
0
998544
A
998544
I
See footnote
Common Stock
2021-10-26
4
C
0
302588
A
1301132
D
Common Stock
2021-10-26
4
C
0
302588
A
1301132
I
See footnote
Common Stock
2021-10-26
4
P
0
312500
16.00
A
1613632
D
Common Stock
2021-10-26
4
P
0
312500
16.00
A
1613632
I
See footnote
Series B Convertible Preferred Stock
2021-10-26
4
C
0
9486166
0.00
D
Common Stock
998544
0
D
Series B Convertible Preferred Stock
2021-10-26
4
C
0
9486166
0.00
D
Common Stock
998544
0
I
See footnote
Series C Convertible Preferred Stock
2021-10-26
4
C
0
2874595
0.00
D
Common Stock
302588
0
D
Series C Convertible Preferred Stock
2021-10-26
4
C
0
2874595
0.00
D
Common Stock
302588
0
I
See footnote
The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.
/s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 Impact Medicine Fund LP
2021-11-03
/s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 (IMF) GP LLP
2021-11-03